Table 7.
Selective active trials of cevostamab in multiple myeloma (MM).
| Trial ID (References) | Drugs | Phase | Enrollment (N) | Trial Title |
|---|---|---|---|---|
| NCT05801939 | Cev | II | 30 | Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy for RRMM |
| NCT05646836 | Cev + Toc +/− XmAb24306 | I | 90 | Open-label, Multicenter Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination with Cevostamab in Patients with RRMM |
| NCT03275103 [146,147] | Cev +/− Toc | I | 420 | Open-Label, Multicenter Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of Cevostamab (BFCR4350A) in Patients with RRMM (CAMMA-3; GO39775) |
| NCT05535244 | Cev + Toc | I/II | 140 | Open-Label, Multi-Cohort Study to Evaluate the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen-Exposed Patients with RRMM (CAMMA-2) |
| NCT04910568 [148] | Cev + Toc + Dex + (Dara or Pom) | I | 184 | Open-Label, Multicenter Trial Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab as Monotherapy and Cevostamab Plus Pomalidomide and Dexamethasone or Cevostamab Plus Daratumumab and Dexamethasone in Patients with RRMM (CAMMA-1) |
Cev = cevostamab; Dara = daratumumab; Dex = dexamethasone; Pom = pomalidomide; RRMM = relapsed and/or refractory multiple myeloma; Toc = tocilizumab.